You are here

ALS

Quanterix sees a bright future for blood biomarkers

Quanterix sees a bright future for blood biomarkers

EP Vantage

Flag link:

Amylyx’s ALS drug could face rejection in Europe

Amylyx’s ALS drug could face rejection in Europe

BioPharma Dive

Flag link:

Apellis abandons ALS drug after study miss

Apellis abandons ALS drug after study miss

BioPharma Dive

Apellis Pharmaceuticals

clinical trials

Flag link:

Wave's ALS-dementia drug crashes out after early-phase flop, dealing further blow to target

Wave's ALS-dementia drug crashes out after early-phase flop, dealing further blow to target

Fierce Biotech

Wave Life Sciences

clinical trials

Flag link:

Amylyx’s ALS drug Relyvrio generates $71.4M in Q1

Amylyx’s ALS drug Relyvrio generates $71.4M in Q1

Medical Marketing and Media

Amylyx Pharmaceuticals

Flag link:

Will Biogen’s Qalsody Be a Catalyst for Gene-Specific ALS Research?

Will Biogen’s Qalsody Be a Catalyst for Gene-Specific ALS Research?

BioSpace

drug development

Flag link:

FDA approves Biogen and Ionis’ Tofersen for rare genetic form of ALS

FDA approves Biogen and Ionis’ Tofersen for rare genetic form of ALS

Medical Marketing and Media

Ionis Pharmaceuticals

Flag link:

As Cytokinetics’s ALS drug fails Phase III, focus turns to cardiomyopathy candidate

As Cytokinetics’s ALS drug fails Phase III, focus turns to cardiomyopathy candidate

Clinical Trials Arena

clinical trials

Flag link:

Apellis’ immune system drug hits a setback in ALS

Apellis’ immune system drug hits a setback in ALS

BioPharma Dive

Apellis Pharmaceuticals

clinical trials

Flag link:

5 FDA decisions to watch in the second quarter

5 FDA decisions to watch in the second quarter

BioPharma Dive

Sarepta Therapeutics

Duchenne Muscular Dystrophy

Seres Therapeutics

Flag link:

Cytokinetics’ pipeline tumble continues after ALS med flops in phase 3 interim look

Cytokinetics’ pipeline tumble continues after ALS med flops in phase 3 interim look

Fierce Biotech

clinical trials

Flag link:

BrainStorm Secures FDA Adcomm for ALS Therapy NurOwn

BrainStorm Secures FDA Adcomm for ALS Therapy NurOwn

BioSpace

BrainStorm Cell Therapeutics

Flag link:

Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement

Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement

Investors Business Daily

Ionis Pharmaceuticals

Flag link:

FDA advisers support conditional clearance of Biogen’s ALS drug

FDA advisers support conditional clearance of Biogen’s ALS drug

BioPharma Dive

Flag link:

Neurofilament as a surrogate endpoint goes on trial in tofersen adcomm

Neurofilament as a surrogate endpoint goes on trial in tofersen adcomm

BioSpace

Ionis Pharmaceuticals

clinical trials

Flag link:

Amylyx’s ALS drug sales impress Wall Street

Amylyx’s ALS drug sales impress Wall Street

BioPharma Dive

Flag link:

QurAlis’ Biomarker-Driven Approach Attracts $88M in Series B

QurAlis’ Biomarker-Driven Approach Attracts $88M in Series B

BioSpace

Flag link:

Clene's Nanocrystal ALS Treatment Bounces Back with Positive Data

Clene's Nanocrystal ALS Treatment Bounces Back with Positive Data

BioSpace

Clene Nanomedicine

Flag link:

The ALS Puzzle Gets Two New Pieces: SYF2 and PIKFYVE

The ALS Puzzle Gets Two New Pieces: SYF2 and PIKFYVE

BioSpace

Flag link:

Pages